TP53 and neoplasm: Here, based on the highly significant correlation between TP53 mutation and AURKA expression in HCC tissue, the alisertib and lenvatinib combination contributes to the anticancer activity against HCC, caused by combination suppressed cell survival in vitro and tumor growth in vivo.